Gene · 2091
NIH grants1,725
NIH grants whose papers are about the gene, through NIH's grant-paper links.
141 to 160 of 1,725
Download this page as JSON| Grant | Title | FBL papers | Newest fiscal year |
|---|---|---|---|
| R01CA080728 | Oncogenic Impact of eIF4E-dependent RNA Export in Cancer | 1 | 2025 |
| R01CA096899 | Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis | 1 | 2025 |
| R01CA098571 | Molecular Mechanisms of eIF4E Mediated Transformation | 1 | 2025 |
| R01CA107469 | Role of EZH2 in Breast Cancer Progression | 1 | 2025 |
| R01CA136367 | Disruption of Cellular RNA Processing by Kaposi's Sarcoma-Associated Herpesvirus | 1 | 2025 |
| R01CA157644 | Central tolerance mechanisms in B-cell malignancies | 1 | 2025 |
| R01CA172310 | Novel Targeted Anticancer Agents from Marine Cyanobacteria | 1 | 2025 |
| R01CA195612 | Molecular modulators of radiation-induced chromosome instability and hematopoietic damage | 1 | 2025 |
| R01CA207513 | Role of KLHL6 inactivation in mature B-cell malignancies | 1 | 2025 |
| R01CA238249 | Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment. | 1 | 2025 |
| R01CA240258 | Mutational cooperativity in TET2-associated hematological malignancies. | 1 | 2025 |
| R01CA250534 | Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer | 1 | 2025 |
| R01CA255721 | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 | 1 | 2025 |
| R01CA258904 | Investigating novel synthetic lethal epigenetic interactions in Acute Myeloid Leukemia | 1 | 2025 |
| R01CA262104 | Regulation of the nucleolar RNA exosome in cancer | 1 | 2025 |
| R01CA262160 | Role of O-GlcNAc-ylation on tumor progression | 1 | 2025 |
| R01CA262804 | Antagonistic role of ARF and ADAR1 in triple-negative breast cancer | 1 | 2025 |
| R01CA262903 | The Role of YY1 in Castration-Resistant Prostate Cancer | 1 | 2025 |
| R01CA263079 | Reprogramming myeloid cells to inhibit cancer development | 1 | 2025 |
| R01CA268519 | Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2091/grants?page=8